Document is current
Any future updates will be listed below
-
Authors
Quinn, Colin H.
Julson, Janet R.
Erwin, Michael H.
Markert, Hooper R.
Bownes, Larua V.
Stewart, Jerry E.
Shirley, Sorina
Yoon, Karina J.
Aye, Jamie M.
Markert, James M.
Beierle, Elizabeth A.
-
Funding
Funding for this research was provided by:
National Institute of Health (5T32GM008361)
National Cancer Institute (T32CA229102)
Open Hands Overflowing Hearts
Sid Strong Foundation
Elaine Roberts Foundation
Kaul Pediatric Research Foundation
- License Information
-
More Information
Article History
Received: 6 October 2024
Accepted: 14 April 2025
First Online: 17 April 2025
Declarations
:
: Dr James M. Markert holds equity (< 8%) in Aettis, Inc. (a company that holds stocks of oncolytic virus); Treovir, Inc (25%), a company holding intellectual property and funding clinical trials of oncolytic virus for pediatric brain tumors. A company that Dr J.M. Markert formerly held equity in (< 8%) Catherex, Inc., was purchased in a structured buyout. Dr J.M. Markert has served as a consultant for Imugene. He also holds a fraction of the IP associated with oncolytic virus C134, which is licensed by Mustang Biotech. The following authors have no competing interest: Colin H. Quinn, Janet R. Julson, Michael H. Erwin, Hooper R. Markert, Laura V. Bownes, Jerry E. Stewart, Sorina Shirley, Karina J. Yoon, Jamie M. Aye, and Elizabeth A. Beierle.
